Monte Rosa Therapeutics (NASDAQ: GLUE) officer reports stock and option holdings in Form 3
Matthew Bowen, Principal Accounting Officer at Monte Rosa Therapeutics (NASDAQ: GLUE), has filed an initial ownership report (Form 3) detailing his holdings. The report indicates he directly owns 21,604 shares of common stock, which includes 3,590 unvested restricted stock units, and holds multiple stock option awards with exercise prices ranging from $5.71 to $23.99 per share, expiring between 2031 and 2036. These options and RSUs are subject to vesting schedules contingent on his continued service with the company.
Does J&J-Backed MRT-2359 Prostate Cancer Trial Change The Bull Case For Monte Rosa Therapeutics (GLUE)?
Monte Rosa Therapeutics recently announced a Q4 2025 net loss and a supply agreement with Johnson & Johnson for a Phase 2 trial of MRT-2359 in metastatic castration-resistant prostate cancer. This collaboration, coupled with early positive data, validates Monte Rosa's molecular glue degrader platform. While the J&J deal and data strengthen MRT-2359 as a key catalyst, they don't fundamentally alter the risk profile related to clinical execution, trial outcomes, and funding needs for the loss-making company.
Does J&J-Backed MRT-2359 Prostate Cancer Trial Change The Bull Case For Monte Rosa Therapeutics (GLUE)?
Monte Rosa Therapeutics recently announced a fourth-quarter 2025 net loss but entered a significant supply agreement with Johnson & Johnson for its molecular glue degrader MRT-2359. This collaboration for a Phase 2 prostate cancer trial, alongside positive early data, validates Monte Rosa's platform and MRT-2359 as a key near-term catalyst. However, despite this external validation, the core investment risks related to clinical execution, trial outcomes, and funding needs for the loss-making company remain central to its investment narrative.
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Johnson & Johnson MRT-2359 Trial Supply Agreement
Monte Rosa Therapeutics (GLUE) is under scrutiny after a trial supply agreement with Johnson & Johnson for its MRT-2359 drug. While its price-to-sales ratio suggests overvaluation compared to its estimated fair value, a Discounted Cash Flow model indicates the stock is undervalued. This creates mixed signals for investors, highlighting the need to review underlying data and potential risks and rewards.
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Consensus Rating of "Moderate Buy" by Brokerages
Monte Rosa Therapeutics (NASDAQ:GLUE) has received a "Moderate Buy" consensus rating from eight brokerages, with an average 1-year target price of $32.80. Despite insider selling totaling $693,692 in the last three months, institutional investors hold nearly 80% of the stock. The company recently missed quarterly expectations, reporting an EPS of ($0.55) against an expected ($0.45) and revenue of $2.78 million compared to expectations of $17.09 million.
Monte Rosa Therapeutics urges new pathways for the next generation of scientists
Monte Rosa Therapeutics is advocating for new pathways to engage individuals early in the scientific process, emphasizing the importance of diversity and inclusion. The company's commitment to nurturing curiosity and supporting leadership among aspiring scientists aligns with an industry-wide focus on talent development in STEM fields. These efforts complement Monte Rosa's ongoing advancements, including moving MRT-2359 into a Phase 2 trial and presenting positive clinical data.
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Its Recent Share Price Pullback
Monte Rosa Therapeutics (GLUE) experienced a 14.5% share price decline recently but has shown strong long-term growth. The article examines the company's valuation using Price-to-Sales (P/S) and Discounted Cash Flow (DCF) models, revealing conflicting signals with the P/S ratio suggesting overvaluation compared to some benchmarks, while the DCF model indicates the stock is undervalued. This presents investors with a mixed picture when assessing its future potential.
Monte Rosa Therapeutics (NASDAQ:GLUE) Downgraded by Wall Street Zen to "Sell"
Wall Street Zen downgraded Monte Rosa Therapeutics (NASDAQ:GLUE) to a "sell" rating, despite other analysts maintaining a "Moderate Buy" consensus with an average price target of $32.80. This downgrade follows the company missing its quarterly EPS and revenue expectations. Monte Rosa Therapeutics' stock
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Monte Rosa Therapeutics reported its Q4 and full-year 2025 financial results and provided several key business updates. The company announced positive interim Phase 1 data for MRT-8102, plans to initiate multiple Phase 2 studies for MRT-8102, MRT-2359, and MRT-6160, and strengthened its balance sheet with a $345 million financing, extending its cash runway into 2029. The updates highlight significant clinical advancement across its pipeline of molecular glue degrader (MGD) medicines.
Wells Fargo Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE)
Wells Fargo maintained a Buy rating on Monte Rosa Therapeutics (GLUE) with a price target of $29.00, following an analyst report from Derek Archila. While TD Cowen also issued a Buy rating, TipRanks – OpenAI downgraded the stock to a Hold. The company recently reported Q4 revenue of $2.78 million and a GAAP net loss of $46.96 million, and corporate insider sentiment is negative due to increased insider selling.
NEA group (NASDAQ: GLUE) discloses 9.6% Monte Rosa ownership
NEA group and its affiliates have filed an amended Schedule 13D, disclosing a 9.6% beneficial ownership stake in Monte Rosa Therapeutics (NASDAQ: GLUE). This decrease in percentage from previous reports is attributed solely to an increase in Monte Rosa's outstanding shares, rather than any transactions by NEA. The filing confirms no recent trading by NEA or its managers and states that the ownership is for investment purposes, with no current plans to change control or corporate structure.
Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results, Misses Estimates By $0.10 EPS
Monte Rosa Therapeutics (NASDAQ:GLUE) announced its latest earnings results, reporting a loss of $0.55 EPS, which missed the consensus estimate by $0.10. The company's revenue of $2.78 million also fell significantly short of the expected $17.09 million. Following the report, shares dropped to $15.77, and analysts currently maintain a "Moderate Buy" rating with an average price target of $32.80 despite recent insider share sales.
Monte Rosa Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Monte Rosa Therapeutics Inc has released its financial results for the quarter ending December 31. This earnings summary was reported by Refinitiv via Reuters, indicating the company's performance for the specified period.
Heart risk, prostate cancer: Monte Rosa data and $345M war chest
Monte Rosa Therapeutics (NASDAQ: GLUE) announced its Q4 and full-year 2025 financial results and provided program updates, highlighting significant clinical progress and financial strength. The company reported strong Phase 1 data for MRT-8102 in reducing inflammation markers and positive PSA responses for MRT-2359 in metastatic prostate cancer. A successful $345 million follow-on financing extends their cash runway into 2029, enabling planned Phase 2 study initiations for multiple programs.
Monte Rosa Therapeutics (GLUE) Quarterly Loss Tests Bullish Profitability Narrative
Monte Rosa Therapeutics posted a Q3 2025 loss of US$0.33 EPS and US$27.1 million net income loss, despite a trailing twelve-month profit of US$20.9 million. The company's revenue has been volatile, from US$84.9 million in Q1 2025 to US$12.8 million in Q3 2025, which complicates the bullish narrative of 44.3% annual revenue growth. With a high P/E of 60.6x compared to peers and a forecast 3.3% annual EPS decline, investors face tension between current valuations and long-term profitability prospects.
Monte Rosa Therapeutics (GLUE) Quarterly Loss Tests Bullish Profitability Narrative
Monte Rosa Therapeutics (GLUE) reported a Q3 2025 net income loss of US$27.1 million and a basic EPS loss of US$0.33, despite its trailing twelve-month revenue reaching US$181.5 million and TTM net income turning positive at US$20.9 million. This quarterly loss and uneven revenue performance challenge the bullish narrative of strong revenue growth and recent profitability, especially given the stock's high P/E ratio of 60.6x compared to peers and a forecast of annual EPS decline. The article highlights the tension between optimistic analyst targets and current financial results, prompting investors to scrutinize the sustainability of its margins and growth projections.
Monte Rosa Therapeutics, Inc. (GLUE) Reports Wider Loss Q4 EPS Estimates by 63.4%
Monte Rosa Therapeutics, Inc. (GLUE) reported a Q4 2025 GAAP loss of $0.55 per share, which is 63.4% wider than the estimated loss of -$0.34. The company's shares traded at $16.02 on a volume of 616,447, resulting in a market capitalization of $1.25 billion. Monte Rosa Therapeutics is a clinical-stage biotechnology company focused on developing novel small molecule precision medicines.
Monte Rosa Therapeutics: Fourth Quarter Financial Results Overview
Monte Rosa Therapeutics (GLUE) reported a fourth-quarter net loss of $46.1 million, or 55 cents per share, which was higher than analysts' expectations of a 47-cent loss. The company's revenue for the quarter was $2.8 million, significantly missing the consensus estimate of $10.3 million. For the full year, Monte Rosa Therapeutics had a net loss of $38.6 million on $123.7 million in revenue.
Monte Rosa Therapeutics (GLUE) 2025 Financials: Q4 Loss, Revenue Miss - News and Statistics
Monte Rosa Therapeutics Inc. (GLUE) reported a Q4 2025 loss of $46.1 million (55 cents per share) and revenue of $2.8 million, missing analyst expectations of a 47-cent loss per share and $10.3 million in revenue. For the full year 2025, the biopharmaceutical firm posted an annual loss of $38.6 million (46 cents per share) and total revenue of $123.7 million. These results indicate a challenging financial period for the Boston-based company.
Monte Rosa Therapeutics: Q4 Earnings Snapshot
Monte Rosa Therapeutics Inc. (GLUE) reported a Q4 loss of $46.1 million, or 55 cents per share, missing analyst expectations of a 47-cent loss. The biopharmaceutical company also fell short on revenue, posting $2.8 million against an estimated $10.3 million. For the entire year, Monte Rosa Therapeutics recorded a loss of $38.6 million and revenue of $123.7 million.
Monte Rosa Therapeutics Q4 revenue drops, net loss widens on lower milestone payments
Monte Rosa Therapeutics reported a decrease in Q4 revenue and a wider net loss, primarily due to lower milestone payments. The company's financial performance in the fourth quarter was impacted by these reduced payments. This news was originally reported by Reuters and Thomson Reuters.
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Monte Rosa Therapeutics reported its Q4 and full-year 2025 financial results and provided business updates, highlighting progress across its clinical programs. The company announced positive interim Phase 1 data for MRT-8102, which showed significant CRP reductions in subjects with elevated cardiovascular disease risk, and plans to initiate multiple Phase 2 studies for MRT-8102, MRT-6160 (in collaboration with Novartis), and MRT-2359. Monte Rosa also strengthened its balance sheet with a $345 million financing, extending its cash runway into 2029.
Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q4 Revenue $2.8M
Monte Rosa Therapeutics, Inc. (GLUE) reported its Q4 revenue of $2.8 million. This financial update follows other recent news for the biotechnology company, including reporting full-year earnings for 2025 and announcing executive changes.
Does Monte Rosa (GLUE)–J&J ERLEADA Supply Deal Reframe GLUE’s MYC Degrader Investment Story?
Monte Rosa Therapeutics has announced a supply agreement with Johnson & Johnson for ERLEADA, to be used in a Phase 2 trial of Monte Rosa's MRT-2359 for metastatic castration-resistant prostate cancer. This collaboration validates MRT-2359's potential and strengthens Monte Rosa's investment narrative, although the company still faces risks related to clinical data, financing, and its current valuation. Investors still need to consider the binary nature of clinical outcomes despite the positive sentiment from the J&J deal.
Advanced prostate cancer trial tests MRT-2359 with J&J’s ERLEADA
Monte Rosa Therapeutics announced a clinical supply agreement with Johnson & Johnson for ERLEADA to support a Phase 2 trial of MRT-2359 in combination with apalutamide for metastatic castration-resistant prostate cancer (mCRPC) patients with AR mutations. The Phase 2 study, targeting up to 25 patients, is expected to start in Q3 2026 and will evaluate efficacy and safety endpoints, following encouraging prior Phase 1/2 data. This collaboration aims to advance a promising combination therapy for advanced prostate cancer patients with limited treatment options.
Monte Rosa Therapeutics Announces Clinical Supply Agreement
Monte Rosa Therapeutics has entered into a supply agreement with Johnson & Johnson to evaluate MRT-2359 in combination with ERLEADA® (apalutamide) for metastatic castration-resistant prostate cancer (mCRPC) patients with androgen receptor (AR) mutations. This collaboration will support a planned Phase 2 study initiating in Q3 2026, aiming to confirm MRT-2359's clinical activity and potentially pave the way for registrational studies. The study builds on compelling clinical activity observed with MRT-2359 in combination with AR inhibition in heavily pretreated mCRPC patients.
Monte Rosa Therapeutics Announces Clinical Supply Agreement
Monte Rosa Therapeutics has entered a clinical supply agreement with Johnson & Johnson for a Phase 2 trial of MRT-2359 combined with apalutamide (ERLEADA®) for metastatic castration-resistant prostate cancer patients with AR mutations. The trial, expected to begin in Q3 2026, aims to confirm the compelling clinical activity observed in earlier studies. Monte Rosa will sponsor the trial and Johnson & Johnson will provide ERLEADA®.
GLUE SEC Filings - Monte Rosa Therapeutics, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Monte Rosa Therapeutics, Inc. (GLUE) SEC filings, including 10-K, 10-Q, and 8-K reports. It details recent significant events such as the termination of an ATM prospectus after a $24.2M raise, a planned $200M public offering, and positive interim clinical data for MRT-8102 and MRT-2359. The content also summarizes quarterly financial results showing collaboration revenue growth and strong cash reserves.
Monte Rosa Therapeutics (GLUE) to Release Quarterly Earnings on Thursday
Monte Rosa Therapeutics (NASDAQ:GLUE) is slated to release its Q4 2025 earnings before the market opens on Thursday, March 19th, with analysts projecting an EPS of ($0.45) and revenue of $17.09 million. The company currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $33.80. Insider sales have occurred, while institutional investors hold a significant portion of the stock.
Monte Rosa Therapeutics (GLUE) Likely to Surpass Earnings Forecasts: Will the Share Price Rise?
Monte Rosa Therapeutics (GLUE) is expected to report a significant year-over-year decline in earnings and revenue for the quarter ending December 2025, but analysts have recently revised EPS estimates upward. With a positive Earnings ESP of +2.13% and a Zacks Rank of #3 (Hold), the company has a favorable chance of exceeding consensus EPS estimates, continuing its streak of beating expectations in previous quarters. Investors are advised to consider both the Earnings ESP and Zacks Rank, along with other market factors, when evaluating GLUE and similar companies like Kyntra Bio (KYNB).
Monte Rosa Therapeutics earnings on deck amid revenue decline
Monte Rosa Therapeutics is set to report its Q4 and full-year 2025 earnings, with analysts expecting a 33-cent loss per share on $15.6 million in revenue, a significant decline from the prior year. Investors will focus on the company's revenue trajectory, cash burn, clinical progress of its lead programs (MRT-2359 and MRT-8102), and potential partnership updates with Novartis and Roche, as the clinical-stage biotech navigates balancing financial pressures with its promising protein degradation platform.
Assessing Monte Rosa Therapeutics (GLUE) Valuation After MRT-2359 Data, Phase 2 Plans And Capital Raise
Monte Rosa Therapeutics (GLUE) is under valuation scrutiny following positive Phase 1/2 data for MRT-2359, outlining Phase 2 plans, and a recent capital raise. Despite a strong year-to-date share price performance, the stock's P/E ratio of 67.3x appears overvalued compared to its estimated fair P/E of 10.9x and projected earnings decline. While analysts anticipate a significant implied upside, a discounted cash flow model suggests the current stock price is closer to its fair value, indicating potential overvaluation concerns tempered by dilution risks and the need for successful execution of its pipeline.
Assessing Monte Rosa Therapeutics (GLUE) Valuation After MRT-2359 Data, Phase 2 Plans And Capital Raise
Monte Rosa Therapeutics (GLUE) is under investor scrutiny following positive Phase 1/2 data for MRT-2359, outlining Phase 2 plans, and a recent capital raise. Despite a strong year-to-date share price performance, the stock's current P/E ratio of 67.3x appears overvalued when compared to declining earnings forecasts and industry averages. A Discounted Cash Flow (DCF) model suggests a fair value closer to the current share price, indicating less upside than analyst targets.
Is Positive MRT-2359 Combo Data at ASCO GU 2026 Altering The Investment Case For Monte Rosa Therapeutics (GLUE)?
Monte Rosa Therapeutics reported positive Phase 1/2 data for its investigational GSPT1 degrader MRT-2359 combined with enzalutamide in metastatic castration-resistant prostate cancer, and plans to advance the regimen to Phase 2. This progress reinforces the investment narrative focusing on their molecular glue degrader platform and upcoming clinical catalysts. However, investors should also consider the company's history of losses, forecast earnings declines, recent dilution, and current high valuation.
Monte Rosa to focus on prostate cancer only for oncology asset MRT-2359
Monte Rosa Therapeutics will narrow the focus of its oncology asset, MRT-2359, to prostate cancer only, based on new clinical data. The decision stemmed from observing promising anti-tumor activity in prostate cancer patients enrolled in its Phase 1/2 clinical trial. This strategic move aims to optimize development given the drug's efficacy in this specific indication.
Dunn Edmund, principal accounting officer, sells Monte Rosa (GLUE) shares for $2496
Edmund Dunn, Principal Accounting Officer at Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), sold 139 shares for $2496 to cover tax obligations from vested restricted stock units. This sale was automatic and occurs as the company's shares are near their 52-week high, with a 196% gain over the past year. Monte Rosa Therapeutics has also recently reported positive clinical trial results and successfully priced a significant public offering to raise approximately $300 million.
Monte Rosa Therapeutics (NASDAQ:GLUE) CEO Markus Warmuth Sells 5,466 Shares
Monte Rosa Therapeutics CEO Markus Warmuth sold 5,466 shares of the company's stock on March 2nd for approximately $97,950.72, reducing his ownership by 0.88%. This follows a previous sale of 5,466 shares in January. Shares of GLUE were up 3.6% to $18.61, and institutions, including State Street Corp, have significantly increased their holdings in the company.
GLUE Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Monte Rosa Therapeutics, Inc. (GLUE), including its income statement, balance sheet, cash flow statement, and key financial ratios for both annual and quarterly periods. The company's financial health is assessed, noting its low profitability but strong cash flow and conservative leverage, though overall financial health is rated as moderate. Key financial metrics such as revenue, EBITDA, net income, and EPS for fiscal year 2024 are highlighted, along with explanations of various financial indicators.
Edmund Dunn of Monte Rosa (GLUE) exercises options, sells 25,700 shares
Monte Rosa Therapeutics principal accounting officer Edmund Dunn exercised stock options and subsequently sold 25,700 common shares in open-market transactions on February 27 and March 2, 2026. The shares were sold at weighted-average prices of $18.1015 and $17.50 per share, after exercising options at $13.41 per share. Post-transaction, Dunn directly holds 22,693 Monte Rosa Therapeutics shares.
Markus Warmuth (GLUE) files Form 144 showing proposed sales and RSU dates
Markus Warmuth, associated with Monte Rosa Therapeutics Inc (GLUE), has filed a Form 144 detailing proposed sales of securities and RSU grant dates. The filing indicates proposed sales of "Common" securities and an RSU stock award granted on January 2, 2025, with a related date of January 2, 2026. It also reports prior sales by Warmuth within the last three months, amounting to 128,372 and 153,759 units, although the specific units (shares or dollar values) are not explicitly stated in the excerpt.
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Positive MRT-2359 Clinical Data Update
Monte Rosa Therapeutics (GLUE) has presented positive updated clinical data for its MRT-2359 prostate cancer program, supporting a move to Phase 2. Despite recent short-term share price declines, the company has seen strong long-term gains. However, its valuation at 67.1x P/E is well above industry averages, though a DCF model suggests it might be undervalued.
Monte Rosa Therapeutics CEO unveils pipeline progress at TD Cowen Health Care Conference
Monte Rosa Therapeutics CEO Markus Warmuth updated the company's pipeline progress at the TD Cowen Health Care Conference. He detailed recent advancements and presented clinical data, specifically focusing on programs developing NEK7 and GSPT1-directed degraders. The presentation underscored the company's therapeutic candidates and their development strategy.
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives Average Recommendation of "Moderate Buy" from Brokerages
Monte Rosa Therapeutics (NASDAQ:GLUE) has received an average recommendation of "Moderate Buy" from nine analysts, with a consensus 1-year price target of $31.33. Recent analyst reports show several firms reiterating "buy" or "outperform" ratings and increasing price targets, despite the stock opening down 4.1% at $17.75. Insider activity includes CEO Markus Warmuth selling a portion of his shares, while institutional investors hold nearly 80% of the company's stock.
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Positive MRT-2359 Clinical Data Update
Monte Rosa Therapeutics (GLUE) recently delivered positive clinical data for its MRT-2359 prostate cancer program, leading to strong long-term share price gains despite recent pullbacks. The company's high P/E ratio of 67.1x suggests a premium valuation compared to industry averages, driven by investor confidence in its pipeline despite forecasted declining earnings. However, a discounted cash flow (DCF) model indicates the stock might be undervalued, trading 43.9% below its estimated future cash flow value.
What Monte Rosa Therapeutics (GLUE)'s Phase 1/2 MRT-2359 Combo Data Means For Shareholders
Monte Rosa Therapeutics reported encouraging Phase 1/2 data for its investigational drug MRT-2359 combined with enzalutamide for prostate cancer patients, showing good tolerability and efficacy signals. The company plans to advance MRT-2359 into a Phase 2 study with a second-generation androgen receptor inhibitor, solidifying its investment narrative. Despite potential risks like revenue contraction and reliance on lead assets, these results bolster sentiment and emphasize the importance of capital-efficient development.
What Monte Rosa Therapeutics (GLUE)'s Phase 1/2 MRT-2359 Combo Data Means For Shareholders
Monte Rosa Therapeutics reported encouraging Phase 1/2 data for its investigational drug MRT-2359 combined with enzalutamide in prostate cancer patients, showing good tolerability and efficacy signals. The company plans to advance MRT-2359 into a Phase 2 study with a second-generation androgen receptor inhibitor, targeting AR-mutant patients. This development strengthens Monte Rosa's investment narrative, emphasizing clinical execution and fundraising needs, though existing concerns about future revenue and earnings remain.
Monte Rosa Therapeutics (GLUE) CMO sells 9,189 shares in open market
Monte Rosa Therapeutics' Chief Medical Officer, Filip Janku, reported an open-market sale of 9,189 shares of company common stock on February 23, 2026, at an average price of $19.4973 per share. Following this transaction, Janku directly owns 65,837 shares of GLUE. This insider activity was disclosed via an SEC Form 4 filing and is characterized as a moderate impact with negative sentiment.
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
Monte Rosa Therapeutics announced updated positive clinical data from its Phase 1/2 study of MRT-2359 in combination with enzalutamide for metastatic castration-resistant prostate cancer (mCRPC) patients. The study showed a 100% PSA response and disease control rate in mCRPC patients with AR mutations, with the combination being well-tolerated. The company plans to initiate a new Phase 2 study in Q3 2026 to further evaluate MRT-2359 in AR mutant patients.
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
Monte Rosa Therapeutics announced updated positive clinical data from its Phase 1/2 study of MRT-2359 in combination with enzalutamide for metastatic castration-resistant prostate cancer (mCRPC) at the ASCO GU Symposium. The data showed a 100% PSA response rate and disease control rate in mCRPC patients with AR mutations, with the combination being generally well-tolerated. The company plans to initiate a new Phase 2 study in Q3 2026 to further evaluate MRT-2359 in AR mutant patients.
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics, Inc. announced its participation in several upcoming investor conferences in March 2026, including the TD Cowen 46th Annual Health Care Conference, Barclays 28th Annual Global Healthcare Conference, and the Jefferies Biotech on the Beach Summit. Management, including CEO Markus Warmuth and CMO Filip Janku, will present or participate in discussions. Webcasts of the events will be available on the company's website.
